<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US7534900 - Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water; chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management"><meta name="DC.contributor" content="Santiago Ini" scheme="inventor"><meta name="DC.contributor" content="Mili Abramov" scheme="inventor"><meta name="DC.contributor" content="Anita Liberman" scheme="inventor"><meta name="DC.contributor" content="Teva Pharmaceutical Industries Ltd" scheme="assignee"><meta name="DC.date" content="2006-3-14" scheme="dateSubmitted"><meta name="DC.description" content="Process for the purification of duloxetine HCl is provided."><meta name="DC.date" content="2009-5-19" scheme="issued"><meta name="DC.relation" content="EP:0273658:A1" scheme="references"><meta name="DC.relation" content="EP:0457559:A2" scheme="references"><meta name="DC.relation" content="EP:0654264:A1" scheme="references"><meta name="DC.relation" content="EP:1506965:A1" scheme="references"><meta name="DC.relation" content="GB:1022031" scheme="references"><meta name="DC.relation" content="US:20040235925:A1" scheme="references"><meta name="DC.relation" content="US:20040249170:A1" scheme="references"><meta name="DC.relation" content="US:20050032782:A1" scheme="references"><meta name="DC.relation" content="US:20060270731:A1" scheme="references"><meta name="DC.relation" content="US:20070167636:A1" scheme="references"><meta name="DC.relation" content="US:3105564" scheme="references"><meta name="DC.relation" content="US:3433804" scheme="references"><meta name="DC.relation" content="US:3468759" scheme="references"><meta name="DC.relation" content="US:3814750" scheme="references"><meta name="DC.relation" content="US:4018895" scheme="references"><meta name="DC.relation" content="US:4194009" scheme="references"><meta name="DC.relation" content="US:4314081" scheme="references"><meta name="DC.relation" content="US:4330546" scheme="references"><meta name="DC.relation" content="US:4956388" scheme="references"><meta name="DC.relation" content="US:5023269" scheme="references"><meta name="DC.relation" content="US:5362886" scheme="references"><meta name="DC.relation" content="US:5491243" scheme="references"><meta name="DC.relation" content="US:5508276" scheme="references"><meta name="DC.relation" content="US:6541668" scheme="references"><meta name="DC.relation" content="WO:2003070720:A1" scheme="references"><meta name="DC.relation" content="WO:2004009069:A1" scheme="references"><meta name="DC.relation" content="WO:2004056795:A1" scheme="references"><meta name="DC.relation" content="WO:2004080468:A1" scheme="references"><meta name="DC.relation" content="WO:2005019199:A1" scheme="references"><meta name="DC.relation" content="WO:2005108386:A1" scheme="references"><meta name="DC.relation" content="WO:2006027798:A2" scheme="references"><meta name="DC.relation" content="WO:2006045255:A1" scheme="references"><meta name="DC.relation" content="WO:2006081515:A2" scheme="references"><meta name="DC.relation" content="WO:2006086809:A1" scheme="references"><meta name="DC.relation" content="WO:2006099433:A1" scheme="references"><meta name="DC.relation" content="WO:2006126213:A1" scheme="references"><meta name="DC.relation" content="WO:2007077580:A2" scheme="references"><meta name="DC.relation" content="WO:2007096707:A2" scheme="references"><meta name="citation_reference" content="Abdel-Monem, et al., &quot;N-Demethylation of Morphine And Structurally Related Compounds With Chloroformate Esters&quot;, J. Med. Chem., 1972, pp. 208-210, vol. 15, No. 2."><meta name="citation_reference" content="Deeter, et al., &quot;Asymmetric Synthesis And Absolute Stereochemistry Of LY248686&quot;, Tetrahedron Letters, 1990, pp. 7101-7104, vol. 31, No. 49."><meta name="citation_reference" content="Fujima, Yoshito et al., &quot;Synthesis of (S)-3-(N-Methylamino)-1-(2-thienyl)propan-1-o1: Revisiting Eli Lilly&#39;s Resolution-Racemization-Recycle Synthesis of Duloxetine for Its Robust Processes,&quot; Organic Process Research &amp; Development, 10(5): 905-913 (2006)."><meta name="citation_reference" content="ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7A, Current Step 4 Version, Nov. 10, 2000."><meta name="citation_reference" content="International Search Report PCT/US2006/009165 mailed Mar. 14, 2006."><meta name="citation_reference" content="International Search Report PCT/US2006/009247 mailed Jul. 24, 2006."><meta name="citation_reference" content="Kamal, et al., &quot;Chemoenzymatic Synthesis of Duloxetine And Its Enantiomer: Lipase-Catalyzed Resolution Of 3-Hydroxy-3-(2-Thienyl) Propanenitrile&quot;, Tetrahedron Letters, 2003, pp. 4783-4787, vol. 44, No. 25."><meta name="citation_reference" content="Kometani, et al., &quot;On The Cleavage Of Tertiary Amines With Ethyl Chloroformate&quot;, Chem. Pharm. Bull., 1976, pp. 342-349, vol. 24, No. 2."><meta name="citation_reference" content="L.A. Sorbera, et al., &quot;Duloxetine Oxalate&quot;, Drugs of the Future, vol. 25, No. 9, pp. 907-916, (2000)."><meta name="citation_reference" content="Sakai, K. et al., &quot;Resolution of 3-(methylamino)-1-(2-thienyl)propan-1-01, a new key intermediate for duloxetine, with (S)-mandelic acid,&quot; Tetrahedron: Asymmetry, 14(12): 1631-1636 (2003)"><meta name="citation_reference" content="Wheeler, et al., &quot;An Asymmetric Synthesis of Duloxetine Hydrochloride, a Mixed Uptake Inhibitor of Serotonin and Norepinephrine, and Its C-14 Labeled Isotopomers&quot;, Journal of Labelled Compounds and Radiopharmaceuticals, 1995, pp. 213-223, vol. 36, No. 3."><meta name="citation_reference" content="Wheeler, W.J., et al., J. &quot;An Symmetric Synthesis Of Duloxetine Hydrochloride, A Mixed Uptake Inhibitor Of Serotonin And Norepinephrine, And Its C-14 Labeled Isotopomers&quot;, Label. Cpds. Radiopharm., 1995, 36, 312."><meta name="citation_patent_number" content="US:7534900"><meta name="citation_patent_application_number" content="US:11/376,552"><link rel="canonical" href="http://www.google.com/patents/US7534900"/><meta property="og:url" content="http://www.google.com/patents/US7534900"/><meta name="title" content="Patent US7534900 - Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water; chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management"/><meta name="description" content="Process for the purification of duloxetine HCl is provided."/><meta property="og:title" content="Patent US7534900 - Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water; chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("1qbpU6SxGYu6oQS0joCwCA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407464522.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("AUS"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("1qbpU6SxGYu6oQS0joCwCA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407464522.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("AUS"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us7534900?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US7534900"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=uva4BQABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS7534900&amp;usg=AFQjCNHGz9__JbPEY2t4M8BZtZmfKDCnIQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US7534900.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US7534900.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20060276660"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US7534900"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US7534900" style="display:none"><span itemprop="description">Process for the purification of duloxetine HCl is provided....</span><span itemprop="url">http://www.google.com/patents/US7534900?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US7534900 - Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water; chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US7534900 - Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water; chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management" title="Patent US7534900 - Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water; chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US7534900 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 11/376,552</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">May 19, 2009</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Mar 14, 2006</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Mar 14, 2005</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2599475A1">CA2599475A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2599478A1">CA2599478A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1858859A1">EP1858859A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1858873A2">EP1858873A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1858874A1">EP1858874A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1874754A1">EP1874754A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060258871">US20060258871</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060270731">US20060270731</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060270861">US20060270861</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060276660">US20060276660</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006099433A1">WO2006099433A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006099457A1">WO2006099457A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006099459A1">WO2006099459A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006099468A2">WO2006099468A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2006099468A3">WO2006099468A3</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">11376552, </span><span class="patent-bibdata-value">376552, </span><span class="patent-bibdata-value">US 7534900 B2, </span><span class="patent-bibdata-value">US 7534900B2, </span><span class="patent-bibdata-value">US-B2-7534900, </span><span class="patent-bibdata-value">US7534900 B2, </span><span class="patent-bibdata-value">US7534900B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Santiago+Ini%22">Santiago Ini</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Mili+Abramov%22">Mili Abramov</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Anita+Liberman%22">Anita Liberman</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Teva+Pharmaceutical+Industries+Ltd%22">Teva Pharmaceutical Industries Ltd</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US7534900.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7534900.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7534900.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (38),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (12),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (2),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (8),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (4)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/7534900&usg=AFQjCNFosu9NaDLlI4vOwMHE4KyMrREWsw">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D7534900&usg=AFQjCNGp-Goos4_cGTwNX8zdsFhqR7rVrQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D7534900B2%26KC%3DB2%26FT%3DD&usg=AFQjCNGrcj1b8hqCZ_V58NGBv_19r5r-fA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT130048619" lang="EN" load-source="ifi">Crystallizing duloxetine HCl in water or a solvent selected from C3-8 ketones, C3-8 esters, C2-8 ethers, C2-8 alcohols, and mixtures thereof with water;  chemically and/or enantiomerically pure; for the treatment of stress urinary incontinence, depression, and pain management</invention-title></span><br><span class="patent-number">US 7534900 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA53244206" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">Process for the purification of duloxetine HCl is provided.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(5)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7534900-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7534900-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7534900-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7534900-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7534900-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7534900-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7534900-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7534900-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7534900-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7534900-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(8)</span></span></div><div class="patent-text"><div mxw-id="PCLM13147059" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A process for the purification of duloxetine HCl, comprising crystallizing duloxetine HCl in water or a solvent selected from the group consisting of C<sub>3-8 </sub>ketones, C<sub>3-8 </sub>esters, C<sub>2-8 </sub>ethers, C<sub>2-8 </sub>alcohols, and mixtures thereof with water.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. The process of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the solvent is selected from the group consisting of acetone, methyl ethyl ketone (MEK), ethyl acetate, methyl t-butyl ether (MTBE), ethanol, isopropanol, and n-butanol.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. The process of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the solvent is isopropanol or a mixture of acetone and water.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. The process of any of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00003">3</claim-ref>, wherein the ratio (vol/vol) of the solvent and water is at least about 97:3 to about 98.25:1.75.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. The process of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the ratio (vol/vol) of the solvent and water is at least about 98:2.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. The process of any of <claim-ref idref="CLM-00001">claims 1</claim-ref> to <claim-ref idref="CLM-00003">3</claim-ref>, wherein the ratio (vol/vol) of the starting duloxetine HCl and the water or solvent is about 1:10.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text">7. The process of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising dissolving starting duloxetine HCl in water or the solvent at reflux temperature.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text">8. The process of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising cooling the duloxeting HCl in water or the solvent, and after cooling, maintaining the solution while stirring for about 10 minutes to about 24 hours.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES18534097" lang="EN" load-source="patent-office" class="description">
    <heading>RELATED APPLICATIONS</heading> <p num="p-0002">This application claims benefit of U.S. Provisional Application Nos. 60/726,502, filed Oct. 12, 2005, 60/736,746, filed Nov. 14, 2005, 60/661,711, filed Mar. 14, 2005, and 60/773,593, filed Feb. 14, 2006</p>
    <heading>FIELD OF THE INVENTION</heading> <p num="p-0003">The present invention relates to a process for the purification of duloxetine hydrochloride.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p num="p-0004">Duloxetine HCl is a dual reuptake inhibitor of the neurotransmitters serotonin and norepinephrine. It is used for the treatment of stress urinary incontinence (SUI), depression, and pain management. It is commercially available as CYMBALTA®. Duloxetine hydrochloride has the chemical name (S)-(+)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine hydrochloric acid salt and the following structure.</p>
    <p num="p-0005">
      <chemistry id="CHEM-US-00001" num="00001"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7534900B2/US07534900-20090519-C00001.png"> <img id="EMI-C00001" he="35.90mm" wi="34.46mm" file="US07534900-20090519-C00001.TIF" alt="Figure US07534900-20090519-C00001" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7534900B2/US07534900-20090519-C00001.png" class="patent-full-image" width="137" height="143"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US07534900-20090519-C00001.CDX"> </attachment> <attachment idref="CHEM-US-00001" attachment-type="mol" file="US07534900-20090519-C00001.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0006">Duloxetine, as well as processes for its preparation, is disclosed in a few published documents, such as U.S. Pat. No. 5,023,269, EP Patent No. 457559 and U.S. Pat. No. 6,541,668.</p>
    <p num="p-0007">The conversion of duloxetine to its hydrochloride salt is described in U.S. Pat. No. 5,491,243 and in Wheeler W. J., et al, <i>J. Label. Cpds.Radiopharm, </i>1995, 36, 312. In both cases the reactions are performed in ethyl acetate.</p>
    <p num="p-0008">Like any synthetic compound, duloxetine HCl can contain extraneous compounds or impurities that can come from many sources. They can be unreacted starting materials, by-products of the reaction, products of side reactions, or degradation products. Impurities in duloxetine HCl or any active pharmaceutical ingredient (API) are undesirable, and, in extreme cases, might even be harmful to a patient being treated with a dosage form of the API in which a sufficient amount of impurities is present. Furthermore, the undesired enantiomeric impurities reduce the level of the API available in the pharmaceutical composition.</p>
    <p num="p-0009">It is also known in the art that impurities in an API may arise from degradation of the API itself, which is related to the stability of the pure API during storage, and the manufacturing process, including the chemical synthesis. Process impurities include unreacted starting materials, chemical derivatives of impurities contained in starting materials, synthetic by-products, and degradation products.</p>
    <p num="p-0010">In addition to stability, which is a factor in the shelf life of the API, the purity of the API produced in the commercial manufacturing process is clearly a necessary condition for commercialization. Impurities introduced during commercial manufacturing processes must be limited to very small amounts, and are preferably substantially absent. For example, the ICH Q7A guidance for API manufacturers requires that process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, such as temperature, pressure, time, and stoichiometric ratios, and including purification steps, such as crystallization, distillation, and liquid-liquid extraction, in the manufacturing process.</p>
    <p num="p-0011">The product mixture of a chemical reaction is rarely a single compound with sufficient purity to comply with pharmaceutical standards. Side products and by-products of the reaction and adjunct reagents used in the reaction will, in most cases, also be present in the product mixture. At certain stages during processing of an API, such as duloxetine hydrochloride, it must be analyzed for purity, typically, by HPLC or TLC analysis, to determine if it is suitable for continued processing and, ultimately, for use in a pharmaceutical product. The API need not be absolutely pure, as absolute purity is a theoretical ideal that is typically unattainable. Rather, purity standards are set with the intention of ensuring that an API is as free of impurities as possible, and, thus, is as safe as possible for clinical use. In the United States, the Food and Drug Administration guidelines recommend that the amounts of some impurities be limited to less than 0.1 percent.</p>
    <p num="p-0012">Generally, side products, by-products, and adjunct reagents (collectively “impurities”) are identified spectroscopically and/or with another physical method, and then associated with a peak position, such as that in a chromatogram or a spot on a TLC plate. (Strobel p. 953, Strobel, H. A.; Heineman, W. R., Chemical Instrumentation: A Systematic Approach, 3rd dd. (Wiley &amp; Sons: New York 1989)).</p>
    <p num="p-0013">(+)-N-methyl-3-(1-naphthalenyloxy)-3-(3-thienyl)propanamine is disclosed by Olsen B. A et al, as an impurity obtained in the preparation of duloxetine (J. Lib. Chrom. &amp; Rel. Technol, 1996, 19, 1993).</p>
    <p num="p-0014">There is a need in the art for a process for preparing chemically and/or enantiomerically pure duloxetine HCl</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p num="p-0015">The present invention encompasses a process for the purification of duloxetine HCl, comprising crystallizing duloxetine HCl in water, or a solvent selected from the group consisting of C<sub>3-8 </sub>ketones, C<sub>3-8 </sub>esters, C<sub>2-8 </sub>ethers, C<sub>2-8 </sub>alcohols, and mixtures thereof with water.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p num="p-0016">As used herein the term “crystallizing” refers to a process comprising: heating a mixture of a starting material and a solvent to a temperature of between about 10° C. below and above the reflux temperature of the solvent to obtain a solution, and cooling the solution to a temperature of about 0° C. to about 30° C.</p>
    <p num="p-0017">The present invention encompasses a process for the purification of duloxetine HCl, comprising crystallizing duloxetine HCl in water or a solvent selected from the group consisting of C<sub>3-8 </sub>ketones, C<sub>3-8 </sub>esters, C<sub>2-8 </sub>ethers, C<sub>2-8 </sub>alcohols, and mixtures thereof with water.</p>
    <p num="p-0018">Preferably, the solvent is selected from the group consisting of acetone, methyl ethyl ketone (MEK), ethyl acetate, methyl t-butyl ether (MTBE), ethanol, isopropanol, and n-butanol. Most preferably, the solvent is a mixture of acetone and water or isopropanol.</p>
    <p num="p-0019">Preferably, when the solvent is in a mixture with water, the ratio (vol/vol) of the solvent and water is about 97:3 to about 98.25:1.75. Preferably, the ratio is at least about 98:2. Preferably, the ratio (vol/vol) of the starting material and the water or solvent is about 1:10. Preferably, the dissolution occurs at reflux temperature. Preferably, after cooling, the solution is maintained while stirring, for about 10 minutes to about 24 hours.</p>
    <p num="p-0020">Preferably, the duloxetine HCl obtained after the crystallization is purer than the duloxetine HCl starting material. To exemplify, the obtained duloxetine HCl contains a lower level of the impurity (+)-N-methyl-3-(1-naphthalenyloxy)-3-(3-thienyl)propanamine (DLX-ISO3) and a lower level of the R-enantiomer of duloxetine.</p>
    <p num="p-0021">The crystallization process may be repeated in order to increase the purification even further either with the same or a different solvent that was used for the first crystallization.</p>
    <p num="p-0022">Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples, describing in detail the analysis of the duloxetine HCl and methods for preparing the duloxetine HCl of the invention.</p>
    <p num="p-0023">It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.</p>
    <heading>EXAMPLES</heading> <p num="h-0007">HPLC Method for Measuring Chemical Purity:</p>
    <p num="p-0024">
      </p> <ul> <li id="ul0001-0001" num="0023">Column: Hypersyl Gold (150×4.6 5μ)</li>
        <li id="ul0001-0002" num="0024">Mobile phase: (A) 63% (KH<sub>2</sub>PO<sub>4 </sub>(0.02M) pH-2.5): 37% (35% MeOH:10% THF) (B) 20% (KH<sub>2</sub>PO<sub>4 </sub>(0.02M) pH-2.5): 80% ACN</li>
        <li id="ul0001-0003" num="0025">Gradient: From 0 to 15 min (A) isocraticaly From 15 to 60 min (B) increases from 0 to 100%</li>
        <li id="ul0001-0004" num="0026">Detection: 230 nm</li>
        <li id="ul0001-0005" num="0027">Flow: 1 mL/min</li>
        <li id="ul0001-0006" num="0028">Detection limit: 0.02%
<br>
HPLC Method for Measuring Enantiomeric Purity:
</li>
        <li id="ul0001-0007" num="0029">Column: Diacel Chiral OD 250×4.6 5μ</li>
        <li id="ul0001-0008" num="0030">Eluent: Hexane (900 mL):IPA (100 mL): DEA(2 mL)</li>
        <li id="ul0001-0009" num="0031">Flow: 1 mL/min</li>
        <li id="ul0001-0010" num="0032">Detection: 230 nm</li>
        <li id="ul0001-0011" num="0033">Sample conc: 0.5 mg/mL</li>
        <li id="ul0001-0012" num="0034">Sample vol: 100 μL</li>
        <li id="ul0001-0013" num="0035">Column temp: 20° C.</li>
        <li id="ul0001-0014" num="0036">Detection limit: 0.02%</li>
      </ul> <heading>Example 1</heading> <heading>Purification of Duloxetine Hydrochloride in Acetone/Water</heading> <heading>Example 1a</heading> <p num="p-0025">A mixture of 20 g Duloxetine hydrochloride in 204 ml acetone/water (98:2) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to 15° C. overnight. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (78 percent yield) containing DLX-ISO3 (0.21 percent) and enantiomer R(&lt;0.03 percent)</p>
    <heading>Example 1b</heading> <p num="p-0026">A mixture of 13 g of the previously obtained Duloxetine hydrochloride in 130 ml acetone/water (98:1.5) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to 10° C. for 2 hours. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (87 percent yield) containing DLX-ISO3 (0.15 percent) and free of enantiomer R.</p>
    <heading>Example 1c</heading> <p num="p-0027">A mixture of 10 g of the previously obtained Duloxetine hydrochloride in 100 ml acetone/water (98:2) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for 1 hour. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (80 percent yield) containing DLX-ISO3 (0.07 percent), and free of enantiomer R.</p>
    <heading>Example 1d</heading> <p num="p-0028">A mixture of 7.5 g of the previously obtained Duloxetine hydrochloride in 75 ml acetone/water (98:2) was heated to reflux. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for 2 hours. The solid was filtered, washed with acetone, and dried in a vacuum oven at 40° C. for 16 hours, giving Duloxetine hydrochloride (73 percent yield) containing DLX-ISO3 (0.03 percent), and free of enantiomer R.</p>
    <heading>Example 2</heading> <heading>Purification of Duloxetine Hydrochloride in Acetone/Water Under Different Conditions</heading> <heading>Example 2a</heading> <p num="p-0029">A mixture of 16 g Duloxetine hydrochloride (contaminated with 0.30 percent DLX-ISO3 and 0.13 percent enantiomer R) in 160 ml acetone was heated to reflux, and then 4 ml of water were added till complete dissolution. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for one hour. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (68 percent yield) containing DLX-ISO3 (0.10 percent) and free of enantiomer R.</p>
    <heading>Example 2b</heading> <p num="p-0030">A mixture of 8 g of the previously obtained Duloxetine hydrochloride in 80 ml acetone was heated to reflux, and 2 ml of water were added. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for half hour. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (36 percent yield) containing DLX-ISO3 (0.06 percent).</p>
    <heading>Example 2c</heading> <p num="p-0031">A mixture of 2 g of the previously obtained Duloxetine hydrochloride in 20 ml of acetone was heated to reflux, and 0.4 ml of water were added. After the compound was dissolved, the oil bath was removed, and the solution was cooled to room temperature and stirred for three hours. The solid was filtered, washed with acetone, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (50 percent yield) free of DLX-ISO3.</p>
    <heading>Example 3</heading> <heading>Purification of Duloxetine Hydrochloride in Ethyl Acetate</heading> <p num="p-0032">A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.46 percent DLX-ISO3 and 0.13 percent enantiomer R) in 10 ml ethyl acetate was heated to reflux, and 50 ml of ethyl acetate were added. The mixture was stirred at the same temperature for 40 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with ethyl acetate, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (93 percent yield) containing DLX-ISO3 (0.28 percent) and 0.07 percent of enantiomer R.</p>
    <p num="p-0033">Example 3 was repeated to yield Duloxetine hydrochloride containing less than 0.14 percent DLX-ISO3.</p>
    <heading>Example 4</heading> <heading>Purification of Duloxetine Hydrochloride in IPA</heading> <heading>Example 4a</heading> <p num="p-0034">A mixture of 8.4 g Duloxetine hydrochloride (contaminated with 0.29 percent DLX-ISO3 and 0.17 percent enantiomer R) in 84 ml IPA was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with IPA, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (62 percent yield) containing DLX-ISO3 (0.21 percent) and free of enantiomer R.</p>
    <heading>Example 4b</heading> <p num="p-0035">A mixture of 8.8 g Duloxetine hydrochloride (contaminated with 0.21 percent DLX-ISO3) in 70 ml IPA was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with IPA, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (83 percent yield) containing DLX-ISO3 (0.17 percent).</p>
    <heading>Example 4c</heading> <p num="p-0036">A mixture of 5 g Duloxetine hydrochloride (contaminated with 0.17 percent DLX-ISO3) in 40 ml IPA was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for two hours. The solid was filtered, washed with IPA, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (65 percent yield) containing DLX-ISO3 (0.13 percent)</p>
    <heading>Example 5</heading> <heading>Purification of Duloxetine Hydrochloride in MTBE/Water</heading> <heading>Example 5a</heading> <p num="p-0037">A mixture of 12 g Duloxetine hydrochloride (contaminated with 0.29 percent DLX-ISO3 and 0.11 percent enantiomer) in 120 ml MTBE was heated to reflux, and 3.6 ml of water were added until complete dissolution. The two phase solution was stirred at the same temperature for 15-30 minutes, followed by cooling to room temperature and stirring overnight. The solid was filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (29 percent yield) containing DLX-ISO3 (0.16 percent) and less than 0.02 percent of enantiomer R.</p>
    <heading>Example 5b</heading> <p num="p-0038">A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.16 percent DLX-ISO3 and less than 0.03 percent of enantiomer R) in 20 ml MTBE is heated to reflux, and 0.36 ml of water are added until complete dissolution. The two phase solution is stirred at the same temperature for 15 to 30 minutes, followed by cooling to room temperature and stirring overnight. The solid is filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (29 percent yield).</p>
    <heading>Example 6</heading> <heading>Purification of Duloxetine Hydrochloride in MEK/Water</heading> <heading>Example 6a</heading> <p num="p-0039">A mixture of 4 g Duloxetine hydrochloride (contaminated with 0.30 percent DLX-ISO3 and 0.17 percent enantiomer R) in 20 ml MEK was heated to reflux, and 0.6 ml of water were added until complete dissolution. The solution was stirred at the same temperature for 15-30 minutes, followed by cooling to 0° to 5° C. and stirring for two hours. The solid was filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (32 percent yield) containing DLX-ISO3 (0.10 percent) and free of enantiomer R.</p>
    <heading>Example 6b</heading> <p num="p-0040">A mixture of 0.5 g Duloxetine hydrochloride (contaminated with 0.10 percent DLX-ISO3) in 2.5 ml MEK is heated to reflux, and 0.1 ml of water are added until complete dissolution. The solution is stirred at the same temperature for 15 to 30 minutes, followed by cooling to 0° to 5° C. and stirring for two hours. The solid is filtered, washed with the same solvents, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (32 percent yield).</p>
    <heading>Example 7</heading> <heading>Purification of Duloxetine Hydrochloride in Water</heading> <p num="p-0041">A mixture of 2.7 g Duloxetine hydrochloride (contaminated with 0.50 percent DLX-ISO3 and 0.29 percent enantiomer R) in 27 ml water was heated to reflux. The solution was stirred at the same temperature for 10 to 15 minutes, followed by cooling to room temperature and stirring overnight. The solid was filtered, washed with water, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (61 percent yield) containing DLX-ISO3 (0.25 percent) and free of enantiomer R.</p>
    <p num="p-0042">Example 7 is repeated to yield Duloxetine hydrochloride containing less than 0.14 percent DLX-ISO3.</p>
    <heading>Example 8</heading> <heading>Purification of Duloxetine Hydrochloride in MEK</heading> <p num="p-0043">A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.26 percent DLX-ISO3 and 0.17 percent enantiomer R) in 40 ml MEK was heated to reflux. The solution was stirred at the same temperature for 30 minutes, followed by cooling to 0° to 5° C. and stirring for 2 hours. The solid was filtered, washed with MEK, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (60 percent yield) contaminated with DLX-ISO3 (0.21 percent) and free of enantiomer R.</p>
    <p num="p-0044">Example 8 is repeated to yield Duloxetine hydrochloride containing less than 0.14 percent DLX-ISO3.</p>
    <heading>Example 9</heading> <heading>Purification of Duloxetine Hydrochloride in Acetone</heading> <heading>Example 9a</heading> <p num="p-0045">A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.46 percent DLX-ISO3 and 0.13 percent enantiomer R) in 130 ml acetone was heated to reflux. The solution was stirred at the same temperature for one hour, followed by cooling to 27° C. The solid was filtered at the same temperature, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (59.50 percent yield) containing DLX-ISO3 (0.17 percent) and free of enantiomer R.</p>
    <heading>Example 9b</heading> <p num="p-0046">A mixture of 1 g Duloxetine hydrochloride (contaminated with 0.17 percent DLX-ISO3) in 65 ml acetone was heated to reflux. The solution was stirred at the same temperature for one hour, followed by cooling to 27° C. The solid was filtered at the same temperature, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (59.50 percent yield).</p>
    <heading>Example 10</heading> <heading>Purification of Duloxetine Hydrochloride in n-butanol</heading> <p num="p-0047">A mixture of 2 g Duloxetine hydrochloride (contaminated with 0.26 percent DLX-ISO3 and 0.17 percent enantiomer R) in 12 ml n-butanol was heated to reflux. The solution was stirred at the same temperature for 10 minutes, followed by cooling to room temperature and stirring for 1 hour. The solid was filtered, washed with n-butanol, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (75 percent yield) containing DLX-ISO3 (0.24 percent, prophetic data) and 0.07 percent of enantiomer R.</p>
    <p num="p-0048">Example 10 is repeated, using a solvent selected from: C<sub>3-5 </sub>ketones, C<sub>3-5 </sub>esters, C<sub>2-5 </sub>ethers, C<sub>2-4 </sub>alcohols other than n-butanol and mixtures thereof with water to yield Duloxetine hydrochloride containing less than 0.14 percent DLX-ISO3.</p>
    <heading>Example 11</heading> <heading>Purification of Duloxetine Hydrochloride in Ethanol</heading> <p num="p-0049">A mixture of 2.22 g Duloxetine hydrochloride (contaminated with 0.28 percent DLX-ISO3 and 0.50 percent enantiomer R) in 22.2 ml ethanol was heated to reflux. The solution was stirred at the same temperature for 15 minutes, followed by cooling to room temperature and stirring for 1 hour. The solid was filtered, washed with n-butanol, and dried in a vacuum oven at 45° C. for 16 hours, giving Duloxetine hydrochloride (36 percent yield) containing DLX-ISO3 (0.21 percent) and free of enantiomer R.</p>
    <p num="p-0050">Example 11 is repeated to yield Duloxetine hydrochloride containing less than 0.14 percent DLX-ISO3.</p>
    <p num="p-0051">While it is apparent that the invention disclosed herein is well calculated to fulfill the objects stated above, it will be appreciated that numerous modifications and embodiments may be devised by those skilled in the art. Therefore, it is intended that the appended claims cover all such modifications and embodiments as falling within the true spirit and scope of the present invention.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3105564">US3105564</a></td><td class="patent-data-table-td patent-date-value">Oct 13, 1960</td><td class="patent-data-table-td patent-date-value">Oct 1, 1963</td><td class="patent-data-table-td ">Ormond Alfred N</td><td class="patent-data-table-td ">Apparatus for measuring static loads</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3433804">US3433804</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 1966</td><td class="patent-data-table-td patent-date-value">Mar 18, 1969</td><td class="patent-data-table-td ">Chemie Linz Ag</td><td class="patent-data-table-td ">Basic-substituted dithienylmethyl- and thienylphenylmethyl ethers and a process of making same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3468759">US3468759</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 9, 1966</td><td class="patent-data-table-td patent-date-value">Sep 23, 1969</td><td class="patent-data-table-td ">Spofa Spojene Farmaceuticke Z</td><td class="patent-data-table-td ">6-azauracil riboside</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3814750">US3814750</a></td><td class="patent-data-table-td patent-date-value">Jun 23, 1972</td><td class="patent-data-table-td patent-date-value">Jun 4, 1974</td><td class="patent-data-table-td ">Pfizer</td><td class="patent-data-table-td ">Basic ethers of 1-phenyl-2-(2-thienyl)ethanols</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4018895">US4018895</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 1975</td><td class="patent-data-table-td patent-date-value">Apr 19, 1977</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Aryloxyphenylpropylamines in treating depression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4194009">US4194009</a></td><td class="patent-data-table-td patent-date-value">Sep 15, 1976</td><td class="patent-data-table-td patent-date-value">Mar 18, 1980</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Antidepressant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4314081">US4314081</a></td><td class="patent-data-table-td patent-date-value">Jan 10, 1974</td><td class="patent-data-table-td patent-date-value">Feb 2, 1982</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Antidepressants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4330546">US4330546</a></td><td class="patent-data-table-td patent-date-value">Sep 3, 1980</td><td class="patent-data-table-td patent-date-value">May 18, 1982</td><td class="patent-data-table-td ">John Wyeth &amp; Brother Limited</td><td class="patent-data-table-td ">Antidepressant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4956388">US4956388</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 1990</td><td class="patent-data-table-td patent-date-value">Sep 11, 1990</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">3-aryloxy-3-substituted propanamines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5023269">US5023269</a></td><td class="patent-data-table-td patent-date-value">Mar 27, 1990</td><td class="patent-data-table-td patent-date-value">Jun 11, 1991</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Inhibit uptake of serotonin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5362886">US5362886</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 1993</td><td class="patent-data-table-td patent-date-value">Nov 8, 1994</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Asymmetric synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5491243">US5491243</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 1994</td><td class="patent-data-table-td patent-date-value">Feb 13, 1996</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Intermediate useful for the asymmetric synthesis of duloxetine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5508276">US5508276</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 1994</td><td class="patent-data-table-td patent-date-value">Apr 16, 1996</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Having duloxetine core, hydroxypropyl methyl cellulose acetate succinate enteric layer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6541668">US6541668</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 2000</td><td class="patent-data-table-td patent-date-value">Apr 1, 2003</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040235925">US20040235925</a></td><td class="patent-data-table-td patent-date-value">Dec 4, 2003</td><td class="patent-data-table-td patent-date-value">Nov 25, 2004</td><td class="patent-data-table-td ">Pharmacia Corporation</td><td class="patent-data-table-td ">preventing a cyclooxygenase-2 mediated disorder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040249170">US20040249170</a></td><td class="patent-data-table-td patent-date-value">Jan 13, 2003</td><td class="patent-data-table-td patent-date-value">Dec 9, 2004</td><td class="patent-data-table-td ">Alfio Borghese</td><td class="patent-data-table-td ">Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20050032782">US20050032782</a></td><td class="patent-data-table-td patent-date-value">May 21, 2004</td><td class="patent-data-table-td patent-date-value">Feb 10, 2005</td><td class="patent-data-table-td ">Cypress Bioscience, Inc.</td><td class="patent-data-table-td ">Treatment of chronic pain associated with drug or radiation therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20060270731">US20060270731</a></td><td class="patent-data-table-td patent-date-value">Mar 14, 2006</td><td class="patent-data-table-td patent-date-value">Nov 30, 2006</td><td class="patent-data-table-td ">Santiago Ini</td><td class="patent-data-table-td ">Pure duloxetine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20070167636">US20070167636</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 2006</td><td class="patent-data-table-td patent-date-value">Jul 19, 2007</td><td class="patent-data-table-td ">Butchko Mark A</td><td class="patent-data-table-td ">Improved process for the asymmetric synthesis of duloxetine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0273658A1?cl=en">EP0273658A1</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 1987</td><td class="patent-data-table-td patent-date-value">Jul 6, 1988</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">3-Aryloxy-3-substituted propanamines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0457559A2?cl=en">EP0457559A2</a></td><td class="patent-data-table-td patent-date-value">May 15, 1991</td><td class="patent-data-table-td patent-date-value">Nov 21, 1991</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Chiral synthesis of 1-aryl-3-aminopropan-1-ols</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0654264A1?cl=en">EP0654264A1</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 1994</td><td class="patent-data-table-td patent-date-value">May 24, 1995</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Treatment of incontinence with venlafaxine or an aryloxy propanamine compound</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1506965A1?cl=en">EP1506965A1</a></td><td class="patent-data-table-td patent-date-value">May 19, 2003</td><td class="patent-data-table-td patent-date-value">Feb 16, 2005</td><td class="patent-data-table-td ">Mitsubishi Rayon Company Limited</td><td class="patent-data-table-td ">Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=uva4BQABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DGB%26NR%3D1022031A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNHQgCIwTBYAmS6Y1_AsF7ptVmUPbw">GB1022031A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003070720A1?cl=en">WO2003070720A1</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2003</td><td class="patent-data-table-td patent-date-value">Aug 28, 2003</td><td class="patent-data-table-td ">Perea Juan Jose Almena</td><td class="patent-data-table-td ">Preparation of n-methyl-3-hydroxy- 3-(2-thienyl)propylamine via novel thiophene derivatives containing carbamate groups as intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004009069A1?cl=en">WO2004009069A1</a></td><td class="patent-data-table-td patent-date-value">Jul 24, 2003</td><td class="patent-data-table-td patent-date-value">Jan 29, 2004</td><td class="patent-data-table-td ">Cypress Bioscience Inc</td><td class="patent-data-table-td ">Treatment of depression secondary to pain (dsp)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004056795A1?cl=en">WO2004056795A1</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 2003</td><td class="patent-data-table-td patent-date-value">Jul 8, 2004</td><td class="patent-data-table-td ">Cipla Ltd</td><td class="patent-data-table-td ">A process for preparing duloxetine and intermediates for use therein</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004080468A1?cl=en">WO2004080468A1</a></td><td class="patent-data-table-td patent-date-value">Mar 5, 2004</td><td class="patent-data-table-td patent-date-value">Sep 23, 2004</td><td class="patent-data-table-td ">Scott Eugene J Van</td><td class="patent-data-table-td ">Improved bioavailability and improved delivery of alkaline pharmaceutical drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005019199A1?cl=en">WO2005019199A1</a></td><td class="patent-data-table-td patent-date-value">Aug 25, 2003</td><td class="patent-data-table-td patent-date-value">Mar 3, 2005</td><td class="patent-data-table-td ">Hetero Drugs Ltd</td><td class="patent-data-table-td ">Amorphous duloxetine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005108386A1?cl=en">WO2005108386A1</a></td><td class="patent-data-table-td patent-date-value">May 11, 2005</td><td class="patent-data-table-td patent-date-value">Nov 17, 2005</td><td class="patent-data-table-td ">Cipla Ltd</td><td class="patent-data-table-td ">Crystalline forms of duloxetine free base</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006027798A2?cl=en">WO2006027798A2</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 2005</td><td class="patent-data-table-td patent-date-value">Mar 16, 2006</td><td class="patent-data-table-td ">Kartik Shantilal Patel</td><td class="patent-data-table-td ">A process for preparation of an antidepressant compound</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006045255A1?cl=en">WO2006045255A1</a></td><td class="patent-data-table-td patent-date-value">Oct 21, 2005</td><td class="patent-data-table-td patent-date-value">May 4, 2006</td><td class="patent-data-table-td ">Zentiva As</td><td class="patent-data-table-td ">Method of manufacturing (s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006081515A2?cl=en">WO2006081515A2</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2006</td><td class="patent-data-table-td patent-date-value">Aug 3, 2006</td><td class="patent-data-table-td ">Teva Pharma</td><td class="patent-data-table-td ">Duloxetine hydrochloride polymorphs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006086809A1?cl=en">WO2006086809A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2006</td><td class="patent-data-table-td patent-date-value">Aug 24, 2006</td><td class="patent-data-table-td ">Fronius Int Gmbh</td><td class="patent-data-table-td ">Device and method for carrying out software updates, and a controller configured for software updates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006099433A1?cl=en">WO2006099433A1</a></td><td class="patent-data-table-td patent-date-value">Mar 14, 2006</td><td class="patent-data-table-td patent-date-value">Sep 21, 2006</td><td class="patent-data-table-td ">Teva Pharma</td><td class="patent-data-table-td ">Pure duloxetine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006126213A1?cl=en">WO2006126213A1</a></td><td class="patent-data-table-td patent-date-value">May 23, 2006</td><td class="patent-data-table-td patent-date-value">Nov 30, 2006</td><td class="patent-data-table-td ">Matrix Lab Ltd</td><td class="patent-data-table-td ">An improved process for the preparation of duloxetine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007077580A2?cl=en">WO2007077580A2</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2007</td><td class="patent-data-table-td patent-date-value">Jul 12, 2007</td><td class="patent-data-table-td ">Msn Lab Ltd</td><td class="patent-data-table-td ">Improved process for pure duloxetine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007096707A2?cl=en">WO2007096707A2</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2006</td><td class="patent-data-table-td patent-date-value">Aug 30, 2007</td><td class="patent-data-table-td ">Medichem Sa</td><td class="patent-data-table-td ">Improved synthesis and preparations of duloxetine salts</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Abdel-Monem, et al., "<a href='http://scholar.google.com/scholar?q="N-Demethylation+of+Morphine+And+Structurally+Related+Compounds+With+Chloroformate+Esters"'>N-Demethylation of Morphine And Structurally Related Compounds With Chloroformate Esters</a>", J. Med. Chem., 1972, pp. 208-210, vol. 15, No. 2.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Deeter, et al., "<a href='http://scholar.google.com/scholar?q="Asymmetric+Synthesis+And+Absolute+Stereochemistry+Of+LY248686"'>Asymmetric Synthesis And Absolute Stereochemistry Of LY248686</a>", Tetrahedron Letters, 1990, pp. 7101-7104, vol. 31, No. 49.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fujima, Yoshito et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+%28S%29-3-%28N-Methylamino%29-1-%282-thienyl%29propan-1-o1%3A+Revisiting+Eli+Lilly%27s+Resolution-Racemization-Recycle+Synthesis+of+Duloxetine+for+Its+Robust+Processes%2C"'>Synthesis of (S)-3-(N-Methylamino)-1-(2-thienyl)propan-1-o1: Revisiting Eli Lilly's Resolution-Racemization-Recycle Synthesis of Duloxetine for Its Robust Processes,</a>" Organic Process Research &amp; Development, 10(5): 905-913 (2006).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7A, Current Step 4 Version, Nov. 10, 2000.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Search Report PCT/US2006/009165 mailed Mar. 14, 2006.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Search Report PCT/US2006/009247 mailed Jul. 24, 2006.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kamal, et al., "<a href='http://scholar.google.com/scholar?q="Chemoenzymatic+Synthesis+of+Duloxetine+And+Its+Enantiomer%3A+Lipase-Catalyzed+Resolution+Of+3-Hydroxy-3-%282-Thienyl%29+Propanenitrile"'>Chemoenzymatic Synthesis of Duloxetine And Its Enantiomer: Lipase-Catalyzed Resolution Of 3-Hydroxy-3-(2-Thienyl) Propanenitrile</a>", Tetrahedron Letters, 2003, pp. 4783-4787, vol. 44, No. 25.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kometani, et al., "<a href='http://scholar.google.com/scholar?q="On+The+Cleavage+Of+Tertiary+Amines+With+Ethyl+Chloroformate"'>On The Cleavage Of Tertiary Amines With Ethyl Chloroformate</a>", Chem. Pharm. Bull., 1976, pp. 342-349, vol. 24, No. 2.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">L.A. Sorbera, et al., "<a href='http://scholar.google.com/scholar?q="Duloxetine+Oxalate"'>Duloxetine Oxalate</a>", Drugs of the Future, vol. 25, No. 9, pp. 907-916, (2000).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sakai, K. et al., "<a href='http://scholar.google.com/scholar?q="Resolution+of+3-%28methylamino%29-1-%282-thienyl%29propan-1-01%2C+a+new+key+intermediate+for+duloxetine%2C+with+%28S%29-mandelic+acid%2C"'>Resolution of 3-(methylamino)-1-(2-thienyl)propan-1-01, a new key intermediate for duloxetine, with (S)-mandelic acid,</a>" Tetrahedron: Asymmetry, 14(12): 1631-1636 (2003)</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wheeler, et al., "<a href='http://scholar.google.com/scholar?q="An+Asymmetric+Synthesis+of+Duloxetine+Hydrochloride%2C+a+Mixed+Uptake+Inhibitor+of+Serotonin+and+Norepinephrine%2C+and+Its+C-14+Labeled+Isotopomers"'>An Asymmetric Synthesis of Duloxetine Hydrochloride, a Mixed Uptake Inhibitor of Serotonin and Norepinephrine, and Its C-14 Labeled Isotopomers</a>", Journal of Labelled Compounds and Radiopharmaceuticals, 1995, pp. 213-223, vol. 36, No. 3.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wheeler, W.J., et al., J. "<a href='http://scholar.google.com/scholar?q="An+Symmetric+Synthesis+Of+Duloxetine+Hydrochloride%2C+A+Mixed+Uptake+Inhibitor+Of+Serotonin+And+Norepinephrine%2C+And+Its+C-14+Labeled+Isotopomers"'>An Symmetric Synthesis Of Duloxetine Hydrochloride, A Mixed Uptake Inhibitor Of Serotonin And Norepinephrine, And Its C-14 Labeled Isotopomers</a>", Label. Cpds. Radiopharm., 1995, 36, 312.</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8278463">US8278463</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 6, 2009</td><td class="patent-data-table-td patent-date-value">Oct 2, 2012</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Process for the preparation of pure duloxetine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20090275760">US20090275760</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 6, 2009</td><td class="patent-data-table-td patent-date-value">Nov 5, 2009</td><td class="patent-data-table-td ">Sujoy Biswas</td><td class="patent-data-table-td ">Process for the preparation of pure duloxetine hydrochloride</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc549/defs549.htm&usg=AFQjCNGCnPB8vsKyTEtdLCsunv3UB46HFw#C549S075000">549/75</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0333120000">C07D333/12</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/38">A61K31/38</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D333/20">C07D333/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=uva4BQABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D333/16">C07D333/16</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/38</span>, <span class="nested-value">C07D333/20</span>, <span class="nested-value">C07D333/16</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Sep 3, 2013</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1-2 AND 6-8 ARE CANCELLED.CLAIMS 3-5 WERE NOT REEXAMINED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120915</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 16, 2012</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 8, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:INI, SANTIAGO;ABRAMOV, MILI;LIBERMAN, ANITA;REEL/FRAME:018076/0084;SIGNING DATES FROM 20060608 TO 20060621</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD;REEL/FRAME:018076/0153</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060719</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U03TAPnz9-wLrgh1rZ7bj6AK7kFRA\u0026id=uva4BQABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3xvOIz18CEC2KEalguCneuhrA-3Q\u0026id=uva4BQABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3oPVI7HKhnneAi8pruPyBO5pdCfQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Crystallizing_duloxetine_HCl_in_water_or.pdf?id=uva4BQABERAJ\u0026output=pdf\u0026sig=ACfU3U1Dmdx-dKRbL11lbe9ermTRSQS52w"},"sample_url":"http://www.google.com/patents/reader?id=uva4BQABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>